Johnson & Johnson – Group report and key figures
A report presented through summary slides of group's operations
Detailed history of financial performances between 2019 and 2024
An overview of the group's major business strategies
A medium-term outlook for opportunities and threats
650 €
WHAT IS THE GROUPS' FINANCIAL SITUATION ?
The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.
WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?
Major portfolio strengthening in Innovative Medecine
Raise competitiveness of MedTech portfolio through strategic M&A
Complete full exit from Consumer Health market
WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?
Through a SWOT analysis, this report also provides an overview of the group's strengths (strong innovation pipeline and a leading global R&D spender, etc.) and weaknesses (the US market accounts for more than half of turnover, etc.).
Exploit the entire Xerfi content library (1,000 studies, 10,000 videos, and hundreds of articles) to produce market research, competitive intelligence, and strategic insights using simple prompts.
Detailed plan
Report scope and market overview
Johnson & Johnson est un groupe pharmaceutique américain créé en 1886. Son activité repose essentiellement sur le développement et la commercialisation de médicaments de prescription, ainsi que sur les technologies médicales. Le pôle Innovative Medicine (64% du CA consolidé en 2025) regroupe notamment l’oncologie, l’immunologie et les neurosciences. La division MedTech (36% du CA) réunit quant à elle la chirurgie, l’orthopédie, le cardiovasculaire et la santé visuelle.
Le chiffre d’affaires de Johnson & Johnson a augmenté de 6% en 2025, pour atteindre 83,4 milliards d’euros. En termes de débouchés, les États-Unis ont représenté 57% des revenus du groupe.Presentation
Segments
SWOT
Related reports
ACCESS THE REPORT
